[1] |
Global strategy for the diagnosis,management and prevention of chronic obstructive pulmonary disease 2022 report[EB/OL]. (2021-11-15). .
|
[2] |
陈亚红,王辰. 2015年更新版GOLD慢性阻塞性肺疾病诊断、治疗和预防的全球策略简介[J]. 中国医学前沿杂志(电子版),2015,7(2):34-39.
|
[3] |
陈亚红. 2017年GOLD慢性阻塞性肺疾病诊断、治疗及预防的全球策略解读[J]. 中国医学前沿杂志(电子版),2017,9(1):37-47. DOI:10.12037/YXQY.2017.01-06.
|
[4] |
陈亚红. 2018年GOLD慢性阻塞性肺疾病诊断、治疗及预防全球策略解读[J]. 中国医学前沿杂志(电子版),2017,9(12):21-33.
|
[5] |
陈亚红. 2019年GOLD慢性阻塞性肺疾病诊断、治疗及预防全球策略解读[J]. 中国医学前沿杂志(电子版),2019,11(1):1-14.
|
[6] |
陈亚红. 2020年GOLD慢性阻塞性肺疾病诊断、治疗及预防全球策略解读[J]. 中国医学前沿杂志(电子版),2019,11(12):32-50. DOI:10.12037/YXQY.2019.12-08.
|
[7] |
陈亚红. 2021年GOLD慢性阻塞性肺疾病诊断、治疗及预防全球策略解读[J]. 中国医学前沿杂志(电子版),2021,13(1):17-39.
|
[8] |
GBD Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory diseases,1990-2017:a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet Respir Med,2020,8(6):585-596. DOI:10.1016/S2213-2600(20)30105-3.
|
[9] |
MONTSERRAT-CAPDEVILA J,MARSAL J R,ORTEGA M,et al.Clinico-epidemiological characteristics of men and women with a new diagnosis of chronic obstructive pulmonary disease:a database(SIDIAP) study[J]. BMC Pulm Med,2021,21(1):44. DOI:10.1186/s12890-021-01392-y.
|
[10] |
FAN H H,WU F,LIU J,et al. Pulmonary tuberculosis as a risk factor for chronic obstructive pulmonary disease:a systematic review and meta-analysis[J]. Ann Transl Med,2021,9(5):390. DOI:10.21037/ATM-20-4576.
|
[11] |
CHERIAN M,JENSEN D,TAN W C,et al. Dyspnoea and symptom burden in mild-moderate COPD:the Canadian Cohort Obstructive Lung Disease Study[J]. ERJ Open Res,2021,7(2):00960-02020. DOI:10.1183/23120541.00960-2020.
|
[12] |
DU Q X,JIN J M,LIU X F,et al. Bronchiectasis as a comorbidity of chronic obstructive pulmonary disease:a systematic review and meta-analysis[J]. PLoS One,2016,11(3):e0150532. DOI:10.1371/journal.pone.0150532.
|
[13] |
NI Y M,SHI G C,YU Y C,et al. Clinical characteristics of patients with chronic obstructive pulmonary disease with comorbid bronchiectasis:a systemic review and meta-analysis[J]. Int J Chron Obstruct Pulmon Dis,2015,10:1465-1475. DOI:10.2147/COPD.S83910.
|
[14] |
GOËRTZ Y M J,LOOIJMANS M,PRINS J B,et al. Fatigue in patients with chronic obstructive pulmonary disease:protocol of the Dutch multicentre,longitudinal,observational FAntasTIGUE study[J]. BMJ Open,2018,8(4):e021745. DOI:10.1136/bmjopen-2018-021745.
|
[15] |
BALASUBRAMANIAN A,MACINTYRE N R,HENDERSON R J,et al. Diffusing capacity of carbon monoxide in assessment of COPD[J]. Chest,2019,156(6):1111-1119. DOI:10.1016/j.chest.2019.06.035.
|
[16] |
DE-TORRES J P,O'DONNELL D E,MARÍN J M,et al. Clinical and prognostic impact of low diffusing capacity for carbon monoxide values in patients with global initiative for obstructive lung diseaseⅠ COPD[J]. Chest,2021,160(3):872-878. DOI:10.1016/j.chest.2021.04.033.
|
[17] |
CASANOVA C,GONZALEZ-DÁVILA E,MARTÍNEZ-GONZALEZ C,et al. Natural course of the diffusing capacity of the lungs for carbon monoxide in COPD:importance of sex[J]. Chest,2021,160(2):481-490. DOI:10.1016/j.chest.2021.03.069.
|
[18] |
CELLI B R,ANDERSON J A,COWANS N J,et al. Pharmacotherapy and lung function decline in patients with chronic obstructive pulmonary disease. A systematic review[J]. Am J Respir Crit Care Med,2021,203(6):689-698. DOI:10.1164/rccm.202005-1854OC.
|
[19] |
JENKINS C R,WEN F Q,MARTIN A,et al. The effect of low-dose corticosteroids and theophylline on the risk of acute exacerbations of COPD:the TASCS randomised controlled trial[J]. Eur Respir J,2021,57(6):2003338. DOI:10.1183/13993003.03338-2020.
|
[20] |
中华医学会呼吸病学分会慢性阻塞性肺疾病学组,中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会. 慢性阻塞性肺疾病诊治指南(2021年修订版)[J]. 中华结核和呼吸杂志,2021,44(3):170-205.
|
[21] |
慢性阻塞性肺疾病糖皮质激素规范管理撰写组. 慢性阻塞性肺疾病糖皮质激素规范管理专家共识(2021版)[J]. 中华结核和呼吸杂志,2021,44(12):1054-1063.
|
[22] |
TAN W C,BOURBEAU J,NADEAU G,et al. High eosinophil counts predict decline in FEV1:results from the CanCOLD study[J]. Eur Respir J,2021,57(5):2000838. DOI:10.1183/13993003.00838-2020.
|
[23] |
PARK H Y,CHANG Y,KANG D,et al. Blood eosinophil counts and the development of obstructive lung disease:the Kangbuk Samsung Health Study[J]. Eur Respir J,2021,58(4):2003823. DOI:10.1183/13993003.03823-2020.
|
[24] |
LIPSON D A,CRIM C,CRINER G J,et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med,2020,201(12):1508-1516. DOI:10.1164/rccm.201911-2207OC.
|
[25] |
MARTINEZ F J,RABE K F,FERGUSON G T,et al. Reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for chronic obstructive pulmonary disease. A randomized,double-blind,multicenter,parallel-group study[J]. Am J Respir Crit Care Med,2021,203(5):553-564. DOI:10.1164/rccm.202006-2618OC.
|
[26] |
FRANCIOSI A N,HOBBS B D,MCELVANEY O J,et al. Clarifying the risk of lung disease in SZ alpha-1 antitrypsin deficiency[J]. Am J Respir Crit Care Med,2020,202(1):73-82. DOI:10.1164/rccm.202002-0262OC.
|
[27] |
LINDENAUER P K,STEFAN M S,PEKOW P S,et al. Association between initiation of pulmonary rehabilitation after hospitalization for COPD and 1-year survival among medicare beneficiaries[J]. JAMA,2020,323(18):1813-1823. DOI:10.1001/jama.2020.4437.
|
[28] |
STONE P W,HICKMAN K,STEINER M C,et al. Predictors of pulmonary rehabilitation completion in the UK[J]. ERJ Open Res,2021,7(1):00509-02020. DOI:10.1183/23120541.00509-2020.
|
[29] |
COX N S,DAL CORSO S,HANSEN H,et al. Telerehabilitation for chronic respiratory disease[J]. Cochrane Database Syst Rev,2021,1(1):CD013040. DOI:10.1002/14651858.CD013040.pub2.
|
[30] |
LIU X,FU C P,HU W P,et al. The effect of Tai Chi on the pulmonary rehabilitation of chronic obstructive pulmonary disease:a systematic review and meta-analysis[J]. Ann Palliat Med,2021,10(4):3763-3782. DOI:10.21037/apm-20-940.
|
[31] |
GOUZI F,MAURY J,HÉRAUD N,et al. Additional effects of nutritional antioxidant supplementation on peripheral muscle during pulmonary rehabilitation in COPD patients:a randomized controlled trial[J]. Oxid Med Cell Longev,2019,2019:5496346. DOI:10.1155/2019/5496346.
|
[32] |
VAN BEERS M,RUTTEN-VAN MÖLKEN M P M H,VAN DE BOOL C,et al. Clinical outcome and cost-effectiveness of a 1-year nutritional intervention programme in COPD patients with low muscle mass:the randomized controlled NUTRAIN trial[J]. Clin Nutr,2020,39(2):405-413. DOI:10.1016/j.clnu.2019.03.001.
|
[33] |
BAFADHEL M,MCKENNA S,AGBETILE J,et al. Aspergillus fumigatus during stable state and exacerbations of COPD[J]. Eur Respir J,2014,43(1):64-71. DOI:10.1183/09031936.00162912.
|
[34] |
HUERTA A,SOLER N,ESPERATTI M,et al. Importance of Aspergillus spp. isolation in acute exacerbations of severe COPD:prevalence,factors and follow-up:the FUNGI-COPD study[J]. Respir Res,2014,15(1):17. DOI:10.1186/1465-9921-15-17.
|
[35] |
BULPA P,DUPLAQUET F,DIMOPOULOS G,et al. Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease exacerbations[J]. Semin Respir Crit Care Med,2020,41(6):851-861. DOI:10.1055/s-0040-1702210.
|
[36] |
GU Y,YE X P,LIU Y X,et al. A risk-predictive model for invasive pulmonary aspergillosis in patients with acute exacerbation of chronic obstructive pulmonary disease[J]. Respir Res,2021,22:176.
|
[37] |
COUTURAUD F,BERTOLETTI L,PASTRE J,et al. Prevalence of pulmonary embolism among patients with COPD hospitalized with acutely worsening respiratory symptoms[J]. JAMA,2021,325(1):59-68. DOI:10.1001/jama.2020.23567.
|
[38] |
FU C P,LIU X,ZHU Q Q,et al. Efficiency of high-flow nasal Cannula on pulmonary rehabilitation in COPD patients:a meta-analysis[J]. Biomed Res Int,2020,2020:7097243. DOI:10.1155/2020/7097243.
|
[39] |
ALSALLAKH M A,SIVAKUMARAN S,KENNEDY S,et al. Impact of COVID-19 lockdown on the incidence and mortality of acute exacerbations of chronic obstructive pulmonary disease:national interrupted time series analyses for Scotland and Wales[J]. BMC Med,2021,19(1):124. DOI:10.1186/s12916-021-02000-w.
|
[40] |
CHAN K P F,MA T F,KWOK W C,et al. Significant reduction in hospital admissions for acute exacerbation of chronic obstructive pulmonary disease in Hong Kong during coronavirus disease 2019 pandemic[J]. Respir Med,2020,171:106085. DOI:10.1016/j.rmed.2020.106085.
|
[41] |
US Preventive Services Task Force,KRIST A H,DAVIDSON K W,et al. Screening for lung cancer:US Preventive Services Task Force recommendation statement[J]. JAMA,2021,325(10):962-970. DOI:10.1001/jama.2021.1117.
|
[42] |
PARK H Y,KANG D,SHIN S H,et al. Chronic obstructive pulmonary disease and lung cancer incidence in never smokers:a cohort study[J]. Thorax,2020,75(6):506-509. DOI:10.1136/thoraxjnl-2019-213732.
|
[43] |
GE F,FENG Y,HUO Z Y,et al. Inhaled corticosteroids and risk of lung cancer among chronic obstructive pulmonary disease patients:a comprehensive analysis of nine prospective cohorts[J]. Transl Lung Cancer Res,2021,10(3):1266-1276. DOI:10.21037/tlcr-20-1126.
|
[44] |
RAYMAKERS A J,MCCORMICK N,MARRA C A,et al. Do inhaled corticosteroids protect against lung cancer in patients with COPD? A systematic review[J]. Respirology,2017,22(1):61-70. DOI:10.1111/resp.12919.
|
[45] |
WU M F,JIAN Z H,HUANG J Y,et al. Post-inhaled corticosteroid pulmonary tuberculosis and pneumonia increases lung cancer in patients with COPD[J]. BMC Cancer,2016,16(1):778. DOI:10.1186/s12885-016-2838-4.
|
[46] |
HIGHAM A,MATHIOUDAKIS A,VESTBO J,et al. COVID-19 and COPD:a narrative review of the basic science and clinical outcomes[J]. Eur Respir Rev,2020,29(158):200199. DOI:10.1183/16000617.0199-2020.
|
[47] |
MILNE S,LI X,YANG C X,et al. Inhaled corticosteroids downregulate SARS-CoV-2-related genes in COPD:results from a randomised controlled trial[J]. Eur Respir J,2021,58(1):2100130. DOI:10.1183/13993003.00130-2021.
|
[48] |
MUNBLIT D,BOBKOVA P,SPIRIDONOVA E,et al. Incidence and risk factors for persistent symptoms in adults previously hospitalized for COVID-19[J]. Clin Exp Allergy,2021,51(9):1107-1120.
|
[49] |
JONES R,DAVIS A,STANLEY B,et al. Risk predictors and symptom features of long COVID within a broad primary care patient population including both tested and untested patients[J]. Pragmat Obs Res,2021,12:93-104. DOI:10.2147/POR.S316186.
|
[50] |
THOMPSON M G,EDWARD S,SHAUN G,et al. Effectiveness of COVID-19 vaccines in ambulatory and inpatient care settings[J]. N Engl J Med,2021,385(15):1355-1371. DOI:10.1056/NEJMOA2110362.
|
[51] |
MARTINEZ F J,AGUSTI A,CELLI B R,et al. Treatment trials in young patients with chronic obstructive pulmonary disease and pre-chronic obstructive pulmonary disease patients:time to move forward[J]. Am J Respir Crit Care Med,2022,205(3):275-287. DOI:10.1164/rccm.202107-1663SO.
|